Mitra Biotech

mitrabiotech.com

Mitra Biotech is a global leader in advancing personalized cancer treatment. We are evolving the personalization of treatment selection and drug development through our phenotypic platforms that reliably predict individual response to tested treatment. Founded in 2010, Mitra is headquartered in Woburn, MA and maintains a significant research and laboratory presence in Bangalore, India. We are committed to developing new technologies that surpass existing biomarker-guided strategies for cancer treatment selection, expanding access to truly personalized medicine, and enhancing the clinical management of cancer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

REGENERON STARTS PHASE REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL

Regeneron | July 07, 2020

news image

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

Read More

KYAN THERAPEUTICS EXCLUSIVELY ENTERS LICENSE AGREEMENT WITH GEORGETOWN UNIVERSITY FOR AI-POWERED CANCER DRUG DEVELOPMENT

KYAN Therapeutics | September 24, 2020

news image

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...

Read More

CELL AND GENE THERAPY

ELASTRIN THERAPEUTICS ANNOUNCES NEWLY FORMED SCIENTIFIC ADVISORY BOARD

Elastrin Therapeutics Inc. | January 17, 2022

news image

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board. The Board is comprised of leading industry and university experts in cardiovascular research and clinical development. Former CMO of Elastrin Therapeutics, Dr. Pedro M. Quintana Diez, will act as chairman. Elastrin Therapeutics’ lead asset ELT-001 is an EDTA...

Read More

CELL AND GENE THERAPY

ULTIMA GENOMICS AND OLINK COLLABORATE TO DEVELOP SOLUTION FOR HIGH-THROUGHPUT PROTEOMICS

Ultima Genomics | June 09, 2022

news image

Olink Holding AB (publ) ("Olink") (Nasdaq: OLK) and Ultima Genomics ("Ultima") today announced that they have entered into a collaboration to enable the use of the Olink® Explore high-throughput proteomics platform with Ultima's sequencing architecture. Ultima Genomics and Olink are working towards a seamless pairing of the existing Olink® Explore assay and Ultima Genomics' sequencing system, and are collaborating with joint customers to enable ...

Read More
news image

REGENERON STARTS PHASE REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL

Regeneron | July 07, 2020

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

Read More
news image

KYAN THERAPEUTICS EXCLUSIVELY ENTERS LICENSE AGREEMENT WITH GEORGETOWN UNIVERSITY FOR AI-POWERED CANCER DRUG DEVELOPMENT

KYAN Therapeutics | September 24, 2020

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...

Read More
news image

CELL AND GENE THERAPY

ELASTRIN THERAPEUTICS ANNOUNCES NEWLY FORMED SCIENTIFIC ADVISORY BOARD

Elastrin Therapeutics Inc. | January 17, 2022

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board. The Board is comprised of leading industry and university experts in cardiovascular research and clinical development. Former CMO of Elastrin Therapeutics, Dr. Pedro M. Quintana Diez, will act as chairman. Elastrin Therapeutics’ lead asset ELT-001 is an EDTA...

Read More
news image

CELL AND GENE THERAPY

ULTIMA GENOMICS AND OLINK COLLABORATE TO DEVELOP SOLUTION FOR HIGH-THROUGHPUT PROTEOMICS

Ultima Genomics | June 09, 2022

Olink Holding AB (publ) ("Olink") (Nasdaq: OLK) and Ultima Genomics ("Ultima") today announced that they have entered into a collaboration to enable the use of the Olink® Explore high-throughput proteomics platform with Ultima's sequencing architecture. Ultima Genomics and Olink are working towards a seamless pairing of the existing Olink® Explore assay and Ultima Genomics' sequencing system, and are collaborating with joint customers to enable ...

Read More